Registration of securities issued in business combination transactions

Subsequent Events - Additional Information (Detail)

v3.7.0.1
Subsequent Events - Additional Information (Detail)
$ in Millions
 1 Months Ended
May 03, 2017
Jan. 05, 2017
USD ($)
Right
shares
Jan. 04, 2017
Jan. 31, 2017
Subsequent Event [Line Items]        
Reversion rights period       90 days
Achieve Life Science, Inc. [Member]        
Subsequent Event [Line Items]        
Conversion of each outstanding share of Achieve common stock , shares converted | shares   4,242.8904    
Termination fee   $ 0.5    
Termination fee upon breach of certain covenants regarding alternative transactions   1.0    
Third party expenses in connection with certain terminations   $ 0.5    
Lock-up period with the execution of the merger agreement     180 days  
Number of contingent value rights to be issued for each share of common stock outstanding | Right   1    
Achieve Life Science, Inc. [Member] | Contingent Value Rights [Member]        
Subsequent Event [Line Items]        
Combined company acquisition period results   5 years    
Aggregate consideration distributed to the holders, consideration received percent   80.00%    
OncoGenex Pharmaceuticals Equityholders [Member] | Achieve Life Science, Inc. [Member]        
Subsequent Event [Line Items]        
Percentage of ownership in combined company   25.00%    
Percentage of outstanding shares of capital stock held by certain officers and directors     1.20%  
Achieve Stockholders [Member] | Achieve Life Science, Inc. [Member]        
Subsequent Event [Line Items]        
Percentage of ownership in combined company   75.00%    
Percentage of outstanding shares of capital stock held by certain officers and directors     78.00%  
Subsequent Event        
Subsequent Event [Line Items]        
Reverse stock split, Common stock 20-for-1